The predominant side effects include: Gastrointestinal symptoms : nausea, vomiting, diarrhoea, constipation, and abdominal pain (affecting 10-50% of patients depending on the specific product and dose, particularly during dose escalation) Injection site reactions : redness, itching, or discomfort at the subcutaneous injection site Hypoglycaemia : particularly when combined with insulin or sulphonylureas Decreased appetite : an intended therapeutic effect that contributes to weight loss However, some patients do report changes in urinary frequency or patterns
However, for pregnant and breastfeeding women, we advise that you consult your doctor prior to intake
Observation times and patient numbers for the analysis of the effect of semaglutide vs comparators on the individual components of MACE are presented in Additional file 5: Appendix Table S5, and show similar results to the composite MACE endpoint
This includes those with kidney disease, thyroid disorders, seizure conditions, or significant cardiovascular history